Introduction
When the Finnish physiologist Robert Tigerstedt and his student, Per Gunnar Bergman, discovered the first component (renin) of the renin-angiotensin system (RAS) at the end of the 19 th century, neither the audience nor the investigators appreciated the impact their discovery would ultimately have on our understanding of cardiovascular diseaseand how to treat it. Now, more than 100 years later, we are beginning to fully unravel the central and complex role of angiotensin II (Ang II) not only in co-ordinating the physiological hormonal cascade regulating renal function, fluid and electrolyte balance, and blood pressure but also in mediating a wide spectrum of pathophysiological processes.
Research on the actions of Ang II has documented the participation of this peptide across the continuum of cardiovascular disease, including hypertension, cardiac failure, and coronary heart disease, post-myocardial infarction (MI) as well as diabetic nephropathy. A considerable body of research on the therapeutic benefits of blocking Ang II in the management of these diseases has come of age. Experimental studies and clinical utilisation of both angiotensin II antagonists (AIIAs), which selectively block the actions of Ang II at its AT 1 receptor, as well as angiotensin-
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converting enzyme (ACE) inhibitors, which inhibit the synthesis of Ang II via ACE, have furthermore contributed greatly to expand our vision of the role of the RAS in cardiovascular and renal disease, as well as revealing the existence of alternate enzymatic pathways, angiotensin peptides, and mechanisms by which this system regulates blood pressure (BP) and tissue perfusion both in normal and disease conditions. The AIIAs, in particular, have proven particularly useful in delineating the pathophysiological role of Ang II in cardiovascular diseases. This is because these agents specifically block Ang II formed from both ACE and non-ACE (e.g., cardiac chymase) sources and also do not impede the additional beneficial haemodynamic and metabolic actions of other biologically active peptides such as bradykinin and angiotensin-(1-7) [Ang- (1) (2) (3) (4) (5) (6) (7) ].
This article summarises our current understanding of the pathological role of Ang II in a wide variety of cardiovascular, renal and other diseases, and reviews the considerable body of research that has accumulated regarding the clinical benefits of selective blockade of the AT 1 receptor in the treatment of hypertension, heart failure, and target organ damage.
The Human Ang II System The RAS has a remarkable history spanning more than 100 years (Table 1) . Beginning with the discovery of renin in crude extracts of kidney in 1898, RAS research has been punctuated at regular intervals by some of the greatest advances in cardiovascular medicine, including, for example, the introduction of ACE inhibitors and AIIAs.
Our current understanding of the basic components of this intricate regulatory system is summarised in Figure 1 . The acid protease renin, released into the circulation from the renal cortical juxtaglomerular apparatus and also released locally in other tissues (e.g., brain, heart, blood vessels), generates angiotensin I (Ang I) from the angiotensinogen precursor primarily synthesised and released from the liver. Ang I is then cleaved by ACE into Ang II, the principal effector of the RAS with a variety of physiological and pathophysiological actions. Ang II interacts with at least two classes of angiotensin (AT) receptor on target tissues: these have been designated AT 1 and AT 2 . These receptors are typical polypeptide (360 amino acid) proteins with seven transmembrane domains. The majority Review 
Figure 1
Key components of the renin-angiotensin system cascade and potential steps to block the system. Angiotensinogen represents the starting point in the production of Ang II. Through the actions of the enzyme renin, Ang I is generated, which is subsequently converted to Ang II by the second proteolytic enzyme ACE. AIIAs block the action of Ang II (generated by ACE and alternative pathways) at the level of the AT1 (but not AT2) receptor. Specific blockers of the AT2 receptor (e.g. PD 123319) are available for experimental but not clinical use. ACE inhibitors block only Ang II generated by ACE and also inhibit the breakdown of other peptides such as bradykinin. Ang-(1-7) and Ang-(1-9) also form part of the RAS and may have important biological activities. Ang-(1-9) is generated from Ang I through the actions of ACE2, whereas Ang-(1-7) is formed from Ang I via the action of several tissue-specific endopeptidases (NEP) or from Ang II via ACE2. Ang-(1-7) may form part of a feedback control mechanism, permitting a balance between the pressor-trophic effects of Ang II and the opposing depressor-antitrophic effects of Ang-(1-7).
of the physiological actions of Ang II, including vasoconstrictive effects, stimulation of aldosterone secretion from the adrenal gland, retention of salt and water, and growth stimulation are mediated by the AT 1 receptor ( Another Ang II receptor (AT 2 ), which might possess counter-regulatory actions against the AT 1 receptor, has also been described and can be blocked by selective AT 2 antagonists such as PD 123319. AT 2 receptors mediate a wide variety of actions, including vasodilatation, inhibition of cell growth, cell differentiation, and apoptosis ( Table 2 ). Although freely expressed during foetal development, AT 2 receptor expression at birth is reduced, thereby allowing the AT 1 receptor to predominate. Several pathological states, including ischaemic heart disease, dilated cardiomyopathy, and atrial fibrillation, are associated with increased AT 2 receptor expression. Indeed, some investigations suggest that the observed beneficial effects of AIIAs might involve inhibition of Ang II at the AT 1 receptor plus stimulation of the unblocked AT 2 receptor.
In addition to the classical pathways of the RAS described above, recent evidence suggests that other novel angiotensin peptides may also be generated ( Figure 1 ). These peptides, including Ang-(1-7) and Ang-(3-8) (Ang IV), may also have important biological activities. 5 Another pathway has also been recently described. In this pathway, the non-biologically active peptide Ang-(1-9) is generated from Ang I through the actions of ACE2, the first human homologue of ACE, whereas Ang-(1-7) is formed from Ang I via the action of several tissue-specific endopeptidases (NEP) or from Ang II via ACE2. Ang-(1-7) can also undergo subsequent metabolism by ACE to another peptide Ang-(1-5), with no known biological activity. As described above, Ang II achieves its biological actions by binding to AT 1 or AT 2 receptors; on the other hand, Ang-(1-7) produces its biological effects such as vasodilatation, natriuresis, diuresis, and antitrophic effects by interacting with a non AT 1 /AT 2 receptor. Ang-(1-7) is the endogenous ligand for the G-protein-coupled receptor mas, the stimulation of which leads to production of nitric oxide (NO) and prostacyclin (PGI2).
Recently, we showed that in cultured rat neonatal myocytes, the anti-hypertrophic actions of Ang-(1-7) were mediated by the coupling of the peptide to the mas receptor. 6 It is now becoming clear that Ang-(1-7) may form part of a feedback control mechanism for the RAS in which this peptide regulates, in an opposing manner, the actions of Ang II. Together, Ang-(1-7) and ANG-II thereby function in a 'ying-yang' manner, permitting a balance between the pressor-trophic effects of Ang II and the opposing depressor-antitrophic effects of Ang-(1-7).
In addition, Ang-(1-7) may also contribute to the antihypertensive effects of both ACE-Is and AIIAs. 5 By preventing ACE-mediated peptide degradation and increasing Ang I availability, ACE inhibition elevates Ang-(1-7). AIIAs also increase Ang-(1-7) by increasing the availability of Ang I (via blockade of AT 1 -mediated negative feedback on renin) and promoting conversion of Ang II to Ang-(1-7) via increased ACE2 expression/activity.
Pharmacological Modulation of RAS
ACE-Is and AIIAs represent the principal pharmacologic methods of inhibiting the RAS. However, other types of agents capable of blocking the RAS are available, including aldosterone receptor blockers (e.g., eplerenone) and renin antagonists (e.g., aliskiren). 
ACE Inhibitors
Initially introduced as antihypertensive agents, ACE-Is have demonstrated clinical efficacy in the treatment of a wide range of cardiovascular and renal diseases, including heart failure, acute MI, chronic renal failure, and sclerodermal renal crisis. ACE-Is arose from early studies performed in the 1960s showing that components of venom from the Brazilian arrowhead viper (Bothrops jararaca) inhibited kinase II, an enzyme involved in the degradation of bradykinin and later found to be identical to ACE. Analogues of the nonpeptide fraction of snake venom (teprotide), which inhibited ACE, were found to lower BP in hypertensive patients and produce beneficial effects in heart failure patients. Subsequent research revealed that ACE inhibition could be achieved by succinyl amino acids (e.g., carboxyalkanoyl and mercaptoalkanoyl derivatives), a finding that ultimately led to the discovery of captopril, the first orally active, competitive ACE-I. Since that time, a plethora of ACE-Is have been developed (enalapril, lisinopril, benazepril, quinapril, ramipril, fosinopril, moexipril and spirapril) that share a common structural moiety that interacts with the zinc ion in the ACE active site.
Angiotensin II Antagonists
AIIAs represent the newest class of drugs introduced to treat hypertension. However, since their initial introduction, AIIAs have demonstrated clinical efficacy in treating left ventricular hypertrophy (LVH), heart failure, diabetic nephropathy, and post-MI. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The development of AIIAs began in the early 1970s with pharmacologic studies of several peptide analogues of Ang II such as saralasin, sarcosine, 1 isoleucine 8 Ang II, and other substitution of amino acids at the C-terminal end of the Ang II molecule. Although potent Ang II antagonists, these compounds retained significant partial agonist activity and had to be administered intravenously, thereby precluding their clinical use. Chemists subsequently synthesised a series of non-peptide AIIAs based on the imidazole and imidazole-5-acetic acid structures and, in an elegant series of molecular manipulations, developed losartan, the first orally active, selective, and potent nonpeptide AIIA. Losartan is metabolised to two derivatives -EXP 3174, which is more potent than losartan at blocking the AT 1 receptor, and the intermediate metabolite EXP 3179, which has low affinity for the AT 1 receptor and may possess anti-inflammatory and platelet anti-aggregatory effects independent of the AT 1 receptor. By employing losartan or its metabolites as a molecular model, chemists have since synthesised a wide range of AIIAs (valsartan, irbesartan, eprosartan, telmisartan, candesartan, and olmesartan).
The clinical effects of the AIIAs arise primarily from their ability to selectively block the interaction between Ang II and the AT 1 receptor present on target tissues; this includes, for example, the afferent and efferent arterioles of the kidney, vascular smooth muscle, and zona glomerulosa of the adrenal gland. AIIAs block the action of Ang II regardless of its site of origin (ACE or non-ACE pathways) and, furthermore, do not produce changes in the metabolism of other biologically active peptides (e.g., bradykinin) which can contribute to development of adverse events (e.g., cough) seen with ACE-Is.
Aldosterone Antagonists
Spironolactone, a non-selective aldosterone antagonist, and eplerenone, both antagonise the effects of aldosterone at its receptor and have demonstrated clinical benefits in patients with hypertension, heart failure, and nephropathy. The addition of eplerenone to standard medical therapy may also represent an interesting new strategy to improve mortality and morbidity particularly in post-MI patients with LV systolic dysfunction and heart failure.
Renin Inhibitors
Burton and colleagues described the first renin inhibitor in 1980, but the substrate analog of angiotensinogen they identified lacked potency and specificity. In the years to follow, a variety of renin inhibitors were synthesised based on substitution of various non-hydrolyzable residues of the scissile bond cleaved by renin. However, limited oral absorption and brief duration of biologic action diminished the clinical usefulness of these agents. Monoclonal antibodies against renin have also been used as molecular probes to study the RAS but have limited clinical utility.
Recently, the first orally active renin inhibitor (aliskiren) has been reported to be effective as an antihypertensive agent both in animals and human subjects. In healthy volunteers, oral aliskiren dose-dependently lowers Ang II levels to a degree equivalent to that seen with enalapril and, in patients with mild-to-moderate hypertension, aliskiren was as effective as irbesartan in lowering BP. However, whether aliskiren treatment results in protection from heart attack, stroke, and nephropathy remains to be investigated.
Involvement of the RAS in Human Health and Disease
During the course of evolutionary development, the RAS has undergone considerable modification and refinement, with the result that this regulatory system has become intricately involved in a wide range of physiological and pathophysiological processes in multiple tissues, organs, and syndromes. 3 There is now a growing body of evidence that enhancement or suppression of the RAS plays a central role in the etiology of a plethora of human diseases (Table 3) , including for example, renin-secreting tumours, scleroderma renal 20 and epidemiological studies have shown a clear association with increased risk of cardiovascular events. For example, a series of epidemiological studies by Alderman and colleagues 21 demonstrated that a low urinary sodium and elevated plasma renin activity represent an independent risk factor for MI and cardiovascular and all-cause mortality. In patients with hypertension, PRA level was found to be independently and directly associated with the incidence of MI, with a 2 unit increase in PRA producing an overall 25% increase in MI incidence ( Figure 2 ). 21
In vivo and in vitro studies of the molecular and cellular effects of Ang II and AIIAs have also provided a wealth of data to demonstrate the involvement of the RAS in cardiovascular and renal diseases, including cardiac hypertrophy/remodelling, cardiac arrhythmias, endothelial dysfunction, vascular remodelling/ atherosclerosis, thrombus formation, platelet aggregation, and nephropathy (Table 4 ). However, the most convincing evidence of the role of the RAS in cardiovascular disease comes from studies in which blockade of AT 1 receptors has been shown to positively impact the morbidity and mortality outcomes of cardiovascular diseases.
Mortality and Morbidity effects of AIlAs -Evidence from Randomised Clinical Trials
A number of outcomes-based mega trials utilising hard clinical endpoints (Table 5) received either a losartan-based or an atenololbased antihypertensive regimen for at least four years and until 1,040 patients had a primary cardiovascular event. An important aspect of the LIFE trial was the fact that it was designed to reflect the manner in which hypertension is treated in actual clinical practice. That is, LIFE employed antihypertensive regimens of multiple medications including a thiazide diuretic and a calcium channel blocker (CCB) or other medication (in addition to losartan or atenolol) to adequately control BP.
For a comparable reduction in BP LIFE revealed that, in patients with hypertension and LVH, a losartan-based regimen prevented Table 4 Involvement of renin-angiotensin system in cardiovascular and renovascular diseases, as evidenced by studies utilising AIIAs. more cardiovascular morbidity and death than an atenolol-based regimen. Losartan produced a 13% relative risk reduction in the composite primary endpoint of cardiovascular mortality, stroke (fatal and non-fatal), and MI (HR 0.87, p=0.021), an effect primarily due to a 25% reduction in the risk of fatal and nonfatal stroke (Figure 3, p=0 .001). 7 The potential public health impact of including losartan as part of a combination antihypertensive therapy regimen for patients with high BP and LVH is substantial. For example, when the benefits of losartan over atenolol in preventing stroke are applied to that fraction of the European Union population who meet LIFE eligibility criteria, it was estimated that using losartan in patients with hypertension and LVH would prevent 125,000 first strokes over a 5.5 year period. 24 Importantly, the cardiovascular and stroke benefits of a losartan-based regimen were accompanied by an excellent tolerability profile. Patients receiving a losartan-based regimen experienced a significantly lower discontinuation rate as a result of all serious adverse events (p<0.0001), drugrelated adverse events (p<0.001), and serious drugrelated adverse events (p=0.006) compared with patients receiving an atenolol-based regimen.
Cardiac remodelling
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A subgroup analysis of LIFE 25 involving hypertensive patients with LVH and a history of atrial fibrillation (n=342) also showed that losartan was more effective than the atenolol-based strategy in lowering the risk of the primary composite endpoint (cardiovascular mortality, stroke and MI) as well as stroke and cardiovascular death. A losartan-based regimen resulted in a significantly lower incidence of the primary composite endpoint (HR=0.58, p=0.009), cardiovascular death (HR=0.58, p=0.048), and stroke (HR=0.55, p=0.039). However, the incidence of MI was similar in the two groups (HR=1.49, p=0.392).
The therapeutic advantage of losartan over atenolol observed in LIFE most likely arises from blockade of the deleterious effects of Ang II mediated by AT 1 receptors as well as from possible molecule-specific effects such as a reduction in serum uric acid levels and inhibition of platelet aggregation. 26 Although LIFE was not designed to evaluate the mechanism(s) by which losartan exerts its anti-stroke effect, several sub-analyses of LIFE data reveal that at least part of the stroke benefit in favour of losartan may be explained by effects on left ventricular mass index, urinary albumin/creatinine ratio, and, possibly, the specific ability of the molecule to reduce serum uric acid levels, and the anti-thrombotic actions of the molecule. [27] [28] [29] Losartan produced a greater regression in LVH compared with atenolol 29 and this effect could have contributed approximately 32% of the advantage of a losartan-based therapy over an atenolol-based therapy on the primary composite endpoint. LIFE data also showed that losartan reduced albuminuria to a greater degree than atenolol for the same degree of reduction in BP, an effect that potentially could have contributed to approximately 20% of the outcome difference in favour of losartan. 27 Another sub-analysis of LIFE data revealed that differences in serum uric acid levels between the losartan and atenolol study groups may also have contributed to the benefit of losartan on the primary composite endpoint (death, MI or stroke). 28 In addition to effects on left ventricular mass, serum uric acid, and urinary albumin, an abundance of experimental and clinical data (Table 4) suggest the potential for losartan to impact stroke risk through a variety of mechanisms, all independent of BP. These include, for example, effects on cardiac remodelling, vascular remodelling, atherosclerosis, endothelial function, thrombus formation, platelet aggregation, and risk factors for stroke.
A recent report 30 has suggested that atenolol, one of the most widely prescribed beta-blockers worldwide, may not represent the most appropriate reference drug in hypertension trials because of a lack of demonstrable superiority of cardiovascular mortality and morbidity benefits compared to placebo or other antihypertensive drugs. On the other hand, the value of atenolol in the prevention of stroke death was amply demonstrated in the landmark study of Systolic Hypertension in the Elderly Program (SHEP), in which the combination of atenolol with chlorthalidone resulted in a 37% decrease in the occurrence of strokes. Additional evidence of the benefits of an atenolol-based therapy is found in results from the International Verapamil -Trandolapril Study (INVEST), where similar outcomes were obtained in patients receiving an atenolol-based strategy compared with those receiving verapamil. 31 The inclusion of atenolol in the LIFE trial is further justified in light of the recent findings of a comprehensive metaanalysis 32 demonstrating that reducing BP using beta-blocker/diuretic regimens is associated with substantial cardiovascular outcomes benefits. This analysis showed that patients who received a beta-blocker (alone or in combination with diuretic) demonstrated a 26% risk reduction in all cardiovascular events (p<0.001), a 19% risk reduction in cardiovascular death (p=0.001), 34% risk reduction in stroke (p<0.001), and a 20% risk reduction in coronary heart disease (p<0.001). These cardiovascular benefits are consistent with the general recognition of beta-blockers as a firstline treatment for hypertension, as outlined by the 7th report of the Joint National Committee on Prevention, Detection and Evaluation, and Treatment of High Blood Pressure, the European Society of Hypertension/European Society of Cardiology, and NICE.
The Study on Cognition and Prognosis in the Elderly (SCOPE) also found that an AIIA (candesartan)-based regimen resulted in a significant 27.8% risk reduction in non-fatal stroke compared with usual antihypertensive treatment in elderly hypertensive patients (p=0.04). 9 However, the primary endpoint (CV death, non-fatal MI, or non-fatal stroke), or secondary endpoint measures of all stroke, fatal stroke, MI, cardiovascular mortality, and percentage of patients with cognitive decline or dementia showed no significant differences between study groups. A small difference in BP (3.2/1.6 mmHg in favour of candesartan) may explain the reduction in non-fatal stroke observed in patients receiving candesartan.
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study evaluated the hypothesis that, for an equivalent degree of BP lowering, the AIIA valsartan would be more effective than the CCB amlodipine in preventing cardiac morbidity and mortality. 8 Hypertensive patients at high risk of cardiac events (n=15,245) were randomised to receive valsartan (80 to 160 mg daily) or amlodipine (5 to 10 mg daily). After a median follow-up of 4.2 years, no differences between the two groups occurred with respect to the primary composite endpoint of cardiac morbidity and mortality or all-cause mortality, although fewer patients in the amlodipine group experienced an MI (HR=1.19, p<0.02). As with the SCOPE study above, the BPs achieved in the two study groups were dissimilar, particularly during the first six months of therapy. For example, fewer valsartan-treated patients than amlodipinetreated patients achieved the combined systolic and diastolic target BP of < 140/90 mmHg (56% vs. 62%, respectively).
Heart Failure
Evidence consistent with a central role of Ang II in the pathophysiology of heart failure comes from three large, randomised double-blind trials -Losartan Heart Failure Survival Study (ELITE II), Valsartan Heart Failure Trial (Val-HeFT), and Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM).
The first major randomised trial (ELITE) of an AIIA in patients with heart failure revealed an unexpected decrease in mortality in losartantreated versus ACE-I-treated patients. 33 However, ELITE II failed to confirm significant differences between losartan and captopril groups with respect to all-cause mortality or all-cause hospitalisation. However, losartan was well tolerated, with approximately 9.7% of patients taking losartan discontinuing study medication due to adverse experiences, compared with 14.7% of patients on captopril (p<0.001). 22 The Val-HeFT compared valsartan with placebo on mortality and morbidity (resuscitated cardiac arrest, hospitalisation for heart failure or administration of an inotropic or vasodilator drug for > 4 hours). 23 As with ELITE II, Val-HeFT studied patients with NYHA class II-IV and ejection fractions less than 40% but differed from ELITE II in that the AIIA (valsartan) was administered twice daily, in addition to usual therapy that included ACE-Is. Although both study groups produced similar effects on all-cause mortality, a significant 13.2% decrease in the combined endpoint of all-cause mortality plus morbidity was apparent in favour of valsartan (p=0.009), an effect due primarily to a 24% decrease in heart failure hospitalisations in valsartan-treated patients (p<0.001). 23 Valsartan also significantly improved NYHA classification, symptoms of heart failure, and health-related quality-of-life assessments (p<0.05).
CHARM represents the most recent outcomes trial in patients with heart failure. 10 CHARM was not a single study but a series of studies carried out concurrently in three different populations of patients with heart failure -CHARM-Added involved patients with ejection fractions of ≤ 40% taking optimum doses of ACE-I; CHARM-Alternative involved heart failure patients with ejection fractions < 40% who were ACE-I intolerant; and CHARM-Preserved involved patients with symptomatic failure and preserved systolic function (ejection fraction > 40%). [11] [12] [13] Each study compared candesartan to placebo as add-on therapy to conventional heart failure treatments such as beta-blockers, diuretics, digitalis, and ACE-Is if appropriate. Results from the individual CHARM-Added and CHARM-Alternative trials revealed that candesartan significantly impacted the primary composite endpoint as well as its individual components and total mortality. However, in CHARM-Preserved, the composite endpoint and cardiovascular death were not significantly different between groups, although candesartan did reduce admissions for heart failure.
Type 2 Diabetes and Renal Disease
Several AIIAs have been shown to slow the progression of renal disease in patients with type 2 diabetes and nephropathy. 16, 17 The Reduction of Endpoints in NIDDM with the Angiotensin Antagonist Losartan (RENAAL) 16 and Irbesartan Diabetic Nephropathy Trial (IDNT) 17 both studied the effect of an AIIA on the time to first event of a composite endpoint (doubling of the serum creatinine concentration, ESRD or death).
RENAAL involved 1,513 patients with severe renal disease that was likely to progress to dialysis and compared losartan (50 or 100 mg once daily) with placebo, in addition to conventional antihypertensive treatment (i.e. CCBs, diuretics, alpha blockers, beta-blockers, and centrally acting agents). 16 Over a follow-up period of 3.4 years, losartan resulted in a 16% risk reduction in the composite endpoint (doubling of serum creatinine concentration, end-stage renal disease (ESRD), or death from any cause, Figure 4 ) and a 28% reduction in the risk of ESRD, compared with placebo (p=0.002).
The renal protective effect of losartan was estimated to produce an average delay of two years in the need for dialysis or transplantation. In addition, losartan significantly decreased the level of proteinuria by approximately 35% compared with placebo-treated patients (p<0.001) as well as decreased the risk of first hospitalisation for heart failure by approximately 32% (p=0.005).
The findings of RENAAL are consistent with a substudy of LIFE trial involving 1,195 patients with hypertension, LVH, and diabetes. 34 A losartan-based regimen was more effective than an atenolol-based regimen in decreasing cardiovascular morbidity and mortality as well as mortality from all causes, despite similar decreases in mean BP. A separate exploratory post hoc analysis of LIFE also suggests that losartan may better protect against cardiac death from arrhythmias than atenolol. 35 IDNT involved 1,715 hypertensive patients with nephropathy due to Type 2 diabetes and compared irbesartan (300 mg daily), amlodipine (10 mg daily), and placebo (conventional antihypertensive treatment) over a mean treatment duration of 2.6 years. 17 In patients receiving irbesartan, the serum creatinine concentration increased approximately 21% more slowly (p=0.02) compared with the amlodipinetreated patients. In addition, irbesartan-treated patients experienced a 20% lower risk of primary composite endpoint of doubling of the baseline serum creatinine concentration, development of ESRD, or death from any cause versus placebo (p=0.02) and a 23% lower risk versus amlodipine (p=0.006). However, unlike RENAAL, IDNT did not show a significant difference in the decline of ESRD among study groups.
Post-MI
The therapeutic benefit of selective antagonism of the AT 1 receptor in post-MI patients has been evaluated in two large trials. The Optimal Therapy In Myocardial infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) 14 investigated the hypothesis that losartan would be superior or non-inferior to captopril in decreasing all-cause mortality in high-risk patients after acute MI. An ACE-I was chosen as an active comparator in this study because of the documented benefits of this class of drugs in improving survival and reducing morbidity in patients with acute MI and cardiac failure.
During a mean follow-up of 2.7 years, losartan and captopril were found to produce similar effects on all-cause mortality, sudden or resuscitated cardiac death, and fatal/nonfatal reinfarction, although captopril therapy was associated with significantly fewer cardiovascular deaths (13.3% vs. 15.3% for losartan, p=0.03). Consistent with the excellent tolerability of the AIIA class of drugs in general, losartan was better tolerated than captopril and gave rise to significantly fewer discontinuations (17% vs. 23%, respectively, p<0.0001).
Similar to the overall findings of OPTIMAAL, VALsartan In Acute myocardial infarction (VALIANT) 15 also found that therapeutically comparable doses of valsartan and captopril produced similar mortality benefits in patients at high risk for cardiovascular events post-MI. In this study, post-MI patients received conventional therapy plus either valsartan alone, valsartan plus captopril, or captopril alone and were followed up for a median of 24.7 months. The occurrence of death from any cause was similar among all three groups, with a hazard ratio of 1.00 (p=0.98) for valsartan group versus captopril and 0.98 (p=0.73) for valsartan plus captopril versus captopril. When the results of OPTIMAAL and VALIANT are analysed together, it is clear that AIIAs may be considered as suitable alternatives to ACE-Is in patients with highrisk acute MI. 36 
Conclusions -What Does the Future Hold?
More than a century of research on the RAS has unveiled some of the most remarkable advances in cardiovascular medicine. The development of selective AIIAs, in particular, has confirmed the pivotal role that Ang II plays in development of a variety of cardiovascular and renal diseases, including hypertension, cardiac failure, coronary heart disease and post-MI, as well as diabetic nephropathy. However, in many respects, we have only just begun to reveal the intricate and diverse physiological and pathophysiological underpinnings of this remarkable regulatory system. Perhaps the next 100 years of research will address many unresolved issues on the mechanism of Ang II-mediated cardiovascular and renal disease and uncover hitherto unimaginable therapeutic opportunities. In the shorter term, several issues are worthy of further study.
Advances in molecular genetic technology have provided a powerful investigational tool in cardiovascular research, and application of this technology is expected to provide further characterisation of the role of Ang II in BP regulation, molecular mechanisms of end-organ injury, and genetic components of hypertension. All of the known genes encoding the principal components of the RAS, including angiotensinogen, renin, ACE, ACE2, and AT 1 /AT 2 and mas receptors, can now be disrupted by gene targeting. This line of research holds great promise for the future, perhaps allowing generation of mice with a humanised genome and identification of background genes capable of modifying RAS genes in vivo.
Ang-(1-7) serves as a feedback control mechanism within the RAS and appears to be critically involved in the control of tissue perfusion, cellcell communication, development, and growth. However, the mechanisms and potential clinical benefits of boosting formation of Ang-(1-7) remain to be delineated. Genomic studies are also needed to determine the possible existence of polymorphisms in the ACE2 gene or Ang-(1-7)forming enzymes.
While most of the cardiovascular effects of Ang II occur via interaction with the AT 1 receptor, we are beginning to recognise that AT 2 receptors may also play a role in pathophysiological processes. Further research is needed to elucidate more clearly the role of AT 2 receptors in cardiovascular diseases and to examine the potential clinical benefits of specifically targeting the AT 2 receptor.
The clinical potential of other agents that impact the RAS such as vasopeptidase inhibitors, renin inhibitors, and aldosterone-receptor blockers represent another area of intense research interest. Aliskiren is a novel, orally effective renin inhibitor that dose-dependently lowers BP in hypertensive patients and appears to have a tolerability profile similar to irbesartan and placebo. Further research is needed to assess whether blocking the RAS at its most upstream point offers any clinical advantages for cardiovascular protection. Peroxisome proliferator-activated receptors (PPARs), a family of ligand-activated nuclear receptors intimately involved in glucose and lipid metabolism, may be involved in the development of several chronic diseases, including diabetes, obesity, atherosclerosis and cancer. There is also evidence to suggest a role for PPARγ in BP control, as indicated by the fact that thiazolidinediones decrease BP in man and animal models with Type 2 diabetes or obesity. Recent studies in vitro demonstrated that some AIIAs (telmisartan and irbesartan) induce PPARγ activity in cultured mouse 3T3-L1 pre adipocytes and increase mRNA levels for PPARγ target genes (aP2 and adiponectin). Although the effects of these agents on human PPAR have yet to be determined, these findings merit further study in man to determine the clinical significance, if any, of the effects of AIIAs on insulin sensitivity, glucose lowering, and cardiovascular outcomes.
Substantial clinical and epidemiological evidence suggests that serum uric acid represents an important risk factor for cardiovascular and renal disease and should be carefully considered when evaluating overall cardiovascular risk in patients with hypertension. Post hoc analysis of data from the LIFE trial raises the possibility that a treatment-induced decrease in serum uric acid may attenuate cardiovascular risk. Although elevated levels of uric acid are associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, haemorheology, and aggregation, further research is needed to determine the pathogenic mechanisms through which uric acid may impact cardiovascular disease. In addition, it would be interesting to evaluate whether a reduction in serum uric acid levels by lifestyle or pharmacologic means would improve the longterm prognosis of patients with hypertension and perhaps other cardiovascular diseases.
The confirmation in the LIFE trial that atherothrombosis represented the majority of the stroke events in the studied population implicates an action of AIIAs in the mechanisms that contribute to hyper-coagulation and thrombosis. The selective effects of some AIIAs in reducing the rate of platelet aggregation and inhibiting inflammatory and atherogenic cytokines needs further investigation since this may represent a novel mechanism by which this treatment approach reduces the risk of thrombotic and embolic effects. 
